Riskpilot← Back to searchSign inGet full accessGlobimed AB
ABDissolvedOrg 5592614993Economic activity was not specified by tax authority · NACE 0000Est. 20200 employees
Revenue 2024
SEK 0
EBITDA margin
—
-172% vs 2023
Equity ratio
-44.2%
Financial strength
Net profit 2024
SEK -36K
-177% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -35K | -172% |
| Net profit | SEK -36K | -177% |
| Total assets | SEK 25K | -34% |
| Equity | SEK -11K | -144% |
| Employees | 0 | — |
Legal name
Globimed AB
Org number
5592614993
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
1 juli 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva konsultverksamhet inom bioteknisk forskning och utveckling, läkemedelsutveckling, specialistläkarverksamhet, förvaltning av fast och lös egendom samt därmed förenlig verksamhet.
Address
Email
felix.sellberg@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | — | — | −13 | −35 |
| Depreciation & amort. | −0 | −0 | −0 | — |
| EBIT | 0 | 0 | −13 | −35 |
| Net financials | — | — | — | −1 |
| Profit before tax | 0 | 0 | −13 | −36 |
| Tax | −0 | −0 | −0 | — |
| Net profit | 0 | 0 | −13 | −36 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 25 | 25 | 38 | 25 |
| Equity | 25 | 25 | 25 | −11 |
| Long-term debt | 0 | 0 | 0 | — |
| Short-term debt | 0 | 0 | 13 | 36 |
| Total debt | — | — | 13 | 36 |
EBITDA margin
-3538000.0%
This company
15.8%
Market median
-22392505% vs market
20212024
Equity ratio
-44.2%
This company
38.2%
Market median
-216% vs market
20212024
Return on equity
-3605500.0%
This company
18.4%
Market median
-19595209% vs market
20212024
Net profit margin
-3605500.0%
This company
8.1%
Market median
-44512446% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
3.26×
This company
0.62×
Market median
-426% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2025 | |
| Board of Directors | 2025 | |
| Former (7) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
| Board of Directors | 2025 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Globimed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robin Gustav Oskar Fröbom | Deputy Board Member | 0 companies |
| Fanny Vieira Fredriksson | Deputy Board Member | 0 companies |
| Olov Andreas Forslund | Deputy Board Member | 0 companies |
| Lennart Patrik Tobias Andersson | Board of Directors | 0 companies |
| Karl David Berglund | Board of Directors | 0 companies |
| Anna-Carina B Helander Anderson | Board of Directors | 0 companies |
| Carl Oscar Andreas Nilsson | Deputy Board Member | 0 companies |
| Virgil Yuan Cheng Xu | Board of Directors | 0 companies |
| Felix Axel Otto Sellberg | Board of Directors | 0 companies |